Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
Reza Shojaei, Executive Leader, Strategic Growth Advisor in Health and Biopharma, shared on LinkedIn:
”Are Hemoglobin Oxygen Carriers (HBOCs) a breakthrough waiting to happen, or just hype?
What if we could deliver oxygen without relying on blood donors, refrigeration, or blood typing?
That’s the bold promise of Hemoglobin Oxygen Carriers (HBOCs), sometimes called “artificial blood.”
Approved in South Africa, tested in Japan, funded by the U.S. military, and eyed for organ preservation in Europe… yet still viewed with caution by regulators.
So, are HBOCs a breakthrough waiting to happen, or just hype?’
In this newsletter edition, we explore:
- Where HBOCs stand today
- Their advantages and safety challenges
- Whether they can truly replace blood donation
- What the global market looks like in 2025
- If they’re viable for low- and middle-income countries”
Read the full Blood and Plasma Pulse newsletter edition here.
Stay updated on the emerging in the field of hematology with Hemostasis Today.
-
Jan 29, 2026, 14:02Emma Lefrancais on Alarmin IL33 and Platelet Biology
-
Jan 29, 2026, 13:44Sia A: One of My Favorite Conversations from ASH
-
Jan 29, 2026, 13:34Sarah Matuja on Tanzania Stroke Project
-
Jan 29, 2026, 13:28Nancy Di Salvo on Amplifying Rare Disease Voices Through Partnership
-
Jan 29, 2026, 13:21Raul Santos Shares The Results of ORION-16: On The Efficacy and Safety of Inclisiran
-
Jan 29, 2026, 05:22Aravind Palraj Draws a Comparison Between APS and Lupus Cerebritis
-
Jan 29, 2026, 05:09Edina Cenko on Expanding Cardiovascular Risk: From Ischaemia to Emerging Frontiers
-
Jan 29, 2026, 04:58Anna Randi Shares the Latest Episode of The VWF and Angiogenesis Story from Her Lab
-
Jan 29, 2026, 04:49Ruah Alyamany on Her Contribution to Establishing The Role of IgM in APS